Regeneron’s RNAi therapy cemdisiran (renamed Livsayis) has received FDA approval for generalized myasthenia gravis, adding a second new MG drug approval in under a week. The launch extends Regeneron’s RNAi platform into a neurologic autoimmune setting and creates a new competitive benchmark for rapid-onset, targeted immunomodulation. The approval also signals a broader shift toward gene-silencing modalities in autoimmune disease, following Regeneron’s earlier RNAi entry points in immunology. For clinicians and payers, the key near-term question will be how rapidly cemdisiran’s real-world safety and durability profile can be established outside trial populations. Taken together with Regeneron’s pipeline updates around autoimmune CAR-T work, the move reframes the company’s development priorities: pairing late-stage RNAi commercialization with near-term expansion of cell-therapy optionality in inflammatory disease. For the market, Livsayis’ arrival tightens the timeline for differentiation versus established antibody and small-molecule options, particularly where disease-control speed and treatment logistics are central decision factors.